A melting structure of formula (I): x-a-ligante-b-z (I) is provided, wherein: (1) a and B are the same or different, and are independent: (a) a polypeptide, including a polypeptide of sacol0029, which is described in any sequence described in table 24 (sections ID Nos.5 and 121-131),1. Sacol0264 polypeptide (ID No: 185)；A sacol0442 polypeptide described in any sequence described in fig.22d (sections 29 and 82-92),1. Sacol0718 polypeptide (section 186)；A sack like peptide 0720 is shown in any sequence described by figs Ibid., sect. 23i-j (Paras. 11 and 109-120).un polip ptido SACOL1353 (SEC ID NO 187)un polip ptido SACOL1416 (SEC ID NO 188)1. Sacol1611 polypeptide (section 189)；5. As shown in any sequence described in fig.25d (ID no.152-164), a sacol1867 polypeptide；1. Sacol 1912 polypeptide (section 43)；1. Board polypeptide, 1944 (CID No. 190)；1. Sacl2144 polypeptide (ID No: 191)；1. Sacl2365 polypeptide (section 192)；a SACOL2385 polypeptide (SEQ ID NO: 50) or a SACOL2599 polypeptide (SEQ ID NO: 193),based on the Staphylococcus aureus COL (SACOL) genome nomenclature exposed in Reference Sequence in NCBI NC_002951.2； (b) a polypeptide encoded by a gene from the same operon as a gene encoding the polypeptide from (a)；(c) Polypeptides, including at least 13 consecutive (a) or (b) amino acid immune fragments；(d) A polypeptide containing at least 60% of the amino acid sequence, completely identical to any one of (a) to (c)；O (E) a polypeptide consisting of at least 13 consecutive amino acids in an immunovariant (a) to (c)；(2) el ligante es una secuencia de amino cidos de por lo menos un amino cido o est ausente (3) X est ausente o es una secuencia de amino cidos de por lo menos un amino cido y (4) Z est ausente o es a SACOL0264 polypeptide (SEQ ID NO 185)a SACOL0442 polypeptide as set forth in any one of the sequences depicted in FIG 22D (SEQ ID NOs 29 and 82 to 92)a SACOL0718 polypeptide (SEQ ID NO 186)a SACOL0720 polypeptide as set forth in any one of the sequences depi
